Menu
Not yet recruiting NCT07569289

Triggering Oocyte Maturation in POSEIDON Group 3 and 4 Poor Responders Using Double Trigger or HCG Trigger

Phase II Interventional Infertility

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Double trigger, HCG trigger.
Who it may be relevant to
Registry conditions: Infertility. Basic parameters: 18 years — 40 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Triggering Oocyte Maturation in POSEIDON Group 3 and 4 Poor Responders Using Double Trigger or HCG Trigger . A Randomized Controlled Study

Overview

The aim of this randomized controlled study is to compare the efficacy of double trigger protocol \[ the co-administration of GnRH agonist with HCG ( 38 - 39 and 35 - 36 h prior to ovum pick-up, respectively \] with HCG in triggering ovulation in patients with expected poor response to ovarian stimulation

Interventions

  • Drug Double trigger
    Triptorelin (0.2 mg/S.C ) and HCG (10000 IU/I.M) are administered 38 to 39 h and 35 to 36 h prior to ovum pick-up., respectively.
  • Drug HCG trigger
    HCG (10000 IU/I.M) is administered 35 to 36 h prior to ovum pick-up.

Primary outcome measures

  • Metaphase-II oocytes rate [Time frame: Ten to fifteen days after starting ovarian stimulation]
Secondary outcome measures (2)
  • Clinical pregnancy rate [Time frame: Five weeks after embryo transfer]
  • Ongoing pregnancy Rate [Time frame: Eighteen weeks after embryo transfer]

Eligibility criteria

Inclusion criteria

  • POSEIDON group 3 and 4
  • GnRH antagonist IVF cycle

Exclusion criteria

  • Hypogonadotrophic hypogonadism
  • Endometriosis
  • History of recurrent abortion

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Bedaya Hospital — Giza

Identifiers

NCT: NCT07569289 · Double trigger/Poor responder

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗